Similarly to the CTLA-4/CD28 dynamic, TIGIT outcompete DNAM-1 (CD226) and CD96 for the binding of CD155, impeding DNAM-1 positive co-stimulation and delivering a direct inhibitory signal [103,104,106] as shown in TIGIT-deficient mice with delayed tumor growth [107]. Here, CD226 is linked to neoplasm.